Effect of insulin therapy on macrovascular risk factors in type 2 diabetes

Diabetes Care

Volumn 22, Issue SUPPL. 3, 1999, Pages

  Boyne, Michael S ^a   Saudek, Christopher D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS;

EID: 0032913579     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (95)

1. Fenig BJ, Simmons DA, Martin DB: Therapy for diabetes. In Diabetes in America. 2nd ed. Harris Ml, Ed. Washington, D.C., U.S. Govt. Printing Office, 1995, p. 520 (NIH publ. no. 95-1468)
2. Fertig BJ, Simmons DA, Martin DB: Therapy for diabetes. In Diabetes in America. 2nd ed. Hams Ml, Ed. Washington, D.C., U.S. Govt. Printing Office, 1995, p. 522 (NIH publ. no. 95-1468)
3. Stout RW: Insulin and atheroma, 20-yr perspective. Diabetes Care 13:611-654, 1990
4. Bierman EL: Atherogenesis in diabetes. ArteriosderThromb 12:647-656, 1992
5. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
6. Juhan-Vague I, Alessi MC, Vague P: Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28:371-380, 1996
7. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE: Coronary hean disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Meteb Res 15 (Suppl.):41-46, 1985
8. Fontbonne A, Charles MA, Thibult N, Richard JL, Calude JR, Warnet JM, Rosselin GE, Eschwege E: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective study, a 15-year follow-up. Diatetologia 34:356-361, 1991
9. Pyorala K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value over 9.5 year follow-up of the Helsinki Policemen Study population. Acta Med Scand 701 (Suppl.):38-52, 1985
10. Perry IJ, Wanamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KGMM: Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 144:224-234, 1996
11. Nabulsi AA, Folsom AR, Heiss G, Weir SS, Chamberless LE, Watson RL, Eckfeldt JH: Fasting hyperinsulinemia and cardiovascular disease risk factors in nondiabetic adults: stronger associations in lean versus obese subjects. Metabolism 44:914-922, 1995
12. Depres JP, Lamarche B, Maunege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
13. Stern MP: The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia 37:956-958, 1994
14. Haffner SM: The insulin resistance syndrome revisited. Diabetes Care 19:275-277, 1996
15. Bonora H, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M: U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population: the Bruneck Study Diabetes Care 21:221-230, 1998
16. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G: Hyperinsulinemia is not a major coronary risk factor in elderly men: the Study of Men Born in 1913. Diabetologia 35:766-770, 1992
17. Nelson RG, Sievers ML, Knowler WC, Swinburn BA, Pettitt DJ, Saad MF, Liebow IM, Howard BV, Bennett PH: Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81:987-995, 1990
18. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA: Insulin as a predictor of coronary heart disease: interaction with apo E phenotype: a report from MRFIT. Ann Epidemiol 4:40-45, 1994
19. Ferrara A, Barrett-Conner EL, Edelstein SL: Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol 140:857-869, 1994
20. Feener EP, King GL: Vascular dysfunction in diabetes mellitus. Lancet 350 (Suppl. 1):9-13, 1997
21. The Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
22. The Diabetes Control and Complications Trial (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
23. McGill HC, McMahan A, Malcolm GT, Oalmann MC, Strong JP: Relation of glycohemoglobin and adiposity in youth. Arterioscler Thromb Vasc Biol 15:431-440, 1995
24. Balkan B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 21:360-367, 1998
25. West KM, Ahuja MMS, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K: The role of circulating glucose and triglyceride concentrations and their interaction with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6:361-369, 1983
26. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR: Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC Study. Circulation 91:1432-1443, 1995
27. Vitelli LL, Shahar E, Heiss G, McGovem PG, Brancati FL, Eckfeldt JH, Folsom AR: Glycosylated hemoglobin level and carotid imimal-medial thickening in nondiabetic individuals. Diabetes Care 20:1454-1458, 1997
28. Hodis HN, Mack WJ, LaBree L, Seber RH, Liu CR, Liu CH, Azen SP: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128:262-269, 1998
29. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41:202-208, 1992
30. Hanefeld M, Fischer S, Julius J, Schwanebeck H, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11 year follow-up. Diabetologia 39:1577-1583, 1996
31. Andersson DKG, Svardsudd K: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
32. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
33. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
34. Fujishima M, Kiyohara Y, Kato, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T: Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study Diabetes 45 tSuppl. 31:S14-S16, 1996
35. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycemia: the Whitehall Study. Br Med J 287:867-870, 1983
36. Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 103:152-162, 1997
37. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
38. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellilus. Ann Intern Med 124:136-145, 1996
39. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 318:823-828, 1998
40. Hiller R, Sperduto RD, Podgor MJ, Ferris FL, Wilson PW: Diabetic retinopathy and cardiovascular disease in type II diabetics. Am J Epidemiol 128:402-409, 1988
41. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes Care 19:1445-1448, 1996
42. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996
43. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, Dejgaard A, Lauritzen M, Lauritzen E, Hougaard P: Prevalence of microand macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetes patients. Diabetologia 34:655-661, 1991
44. Ito H, Harano Y, Suzuki M, Hattori Y, Takeuchi M, Inada H, Inoue J, Kawamori R, Murase T, Ouchi Y, Umeda F, Nawata H, Orimo H: Risk factor analyses for macrovascular complications in nonobese NIDDM. Diabetes 45 (Suppl. 3):S19-S23, 1996
45. Meigs JB, Singer DE, Sullivan L, Dukes KA, D'Agostino RB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus: the NIDDM Patient Outcomes Research Team. Am J Med 102:38-47, 1997
46. Haffner SM, Mitchell BD, Stern MR Hazuda HP: Macrovascular complications in Mexican Americans with type II diabetes. Diabetes Care 14 (Suppl. 3):665-671, 1991
47. Klemman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DW: Mortality among diabetics in a national sample. Am J Epidemiol 128:389-401, 1988
48. Liu QZ, Knowler WC, Nelson RG, Saad MF, Charles MA, Liebow IM, Bennett PH, Pettitt DJ: Insulin treatment, endogenous insulin concentration and ECG abnormalities in diabetic Pima Indians. Diabetes 41:1141-1150, 1992
49. Janka HU, Ziegler AG, Standl E, Mehnert H: Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabete Metab 13:359-364, 1987
50. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIAGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995
51. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA 240:37-42, 1978
52. Genuth J: Exogenous insulin administration and cardiovascular risk in NIDDM and IDDM. Ann Intern Med 124:104-109, 1996
53. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
54. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
55. UKPDS Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
56. UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-856, 1998
57. Laakso M, Lehto S, Penttila I, Pyorala K: Lipids and Hpoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430, 1993
58. Castelli WP: Cardiovascular disease and multi-factorial risk: challenge for the 1980s. Am Heart J 153:1528-1538, 1983
59. Austin MA, Breslow JL, Hennekens CHD, Buring JE, Willett WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1920, 1988
60. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance in individuals with small, dense lipoprotein particles. J Clin Invest 92:141-146, 1993
61. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD: Levels of lipoprotein (a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
62. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. J Am Med Assoc 280:140-146, 1998
63. Cusi K, Cuningham GR, Comstock JP: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18:843-851, 1995
64. Taskinen MR, Kuusi T, HelveE, Nikkila EA, Yki-Jarvinen H: Insulin therapy induces anti-atherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8:168-177, 1988
65. Taskinen MR, Packard CJ, Shepherd J: Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017-1027, 1990
66. Paisey R, Elkeles RS, Hambley J, Magill P: The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 15:81-85, 1978
67. Rabkin SW, Boyko E, Streja DA: Changes in high density lipoprotein cholesterol after initiation of insulin therapy in noninsulin-dependent diabetes mellitus: relationship to changes in body weight. Am J Med Sci 285:14-20, 1983
68. Hollenbeck CB, Chen YD, Greenfield MS, Lardinois CK, Reaven GM: Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 62:605-608, 1986
69. Agardh CD, Nilsson-Ehle P, Schersten B: Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 5:322-325, 1982
70. Caixas A, Perez A, Ordonez-Llanos J, Bonet R, Rigla M, Castellvi A, Bayen L, De Leiva A: Lack of change of lipoprotein (a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients. Diabetes Care 20:1459-1461, 1997
71. Ruotolo G, Parlavecchia M, Taskinen M, Galimberti G, Zoppo A, Le NA, Ragogna F, Micossi P, Pozza G: Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Diabetes Care 17:6-12, 1994
72. Georgopoulos A, Saudek CD: Insulin infusion with a programmable implantable medication system tends to normalize composition of triglyceride-rich lipoprotein subfractions in diabetic subjects. Diabetes Care 15:19-26, 1992
73. Georgopoulos A, Saudek CD: Intraperitoneal insulin delivery decreases the levels of chylomicron remnants in patients with IDDM. Diabetes Care 17:1295-1299, 1994
74. American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 21:179-182, 1998
75. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 21:160-178, 1998
76. Anderson EA, Mark AL: The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 21:136-141, 1993
77. Brands MW, Hildebrandt DA, Mizelle HL, Hall JE: Sustained hyperinsulinemia increases arterial pressure in conscious rats. Am J Physiol 260:R764-R768, 1991
78. Brands MW, Hopkins TE: Poor glycemic control induces hypertension in diabetes mellitus. Hypertension 27:735-739, 1996
79. Hall JE, Brands MW, Kivlighn SD, Mizelle HL, Hildebandt DA, Gaillard CA: Chronic hyperinsulinemia and blood pressure: interaction with catecholammes? Hypertension 15:519-527, 1990
80. Saudek CD, Boulter PR, Arky RA: Sodium retention upon treatment of diabetes mellitus with insulin. Diabetes 23:240-249, 1974
81. Randeree HA, Omar MAK, Motala AA, Seedat MA: Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 15:1258-1263, 1992
82. Tedde R, Sechi LA, Marigliano A, Pala A, Scano L: Antihypertensive effect on insulin reduction in diabetic-hypertensive patients Am J Hypertens 2:163-170, 1989
83. Tsutsu N, Nunoi K, Kodama T, Nomiyama R, Iwase M, Fujishima M: Lack of association between blood pressure and insulin in patients with insulinoma. J Hypertens 8:479-482, 1990
84. Zimmerman S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR: Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Gin Endocrinol Metab 75:508-513, 1992
85. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47:457-463, 1998
86. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
87. Yki-Jarvinen H, Rays L, Kuala M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppala P, Tulokas T, Viikari J, Taskinen MR: Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037-4043, 1997
88. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type 2 diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
89. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 12:623-629, 1989
90. Lindstrom T, Eriksson P, Olsson AG, Amqvist HJ: Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 17:719-721, 1994
91. Wing RR, Klein R, Moss SE: Weight gain associated with improved glycemic control in population-based sample of subjects with type 1 diabetes. Diabetes Care 13:1106-1109, 1990
92. Carlson MG, Campbell PJ: Intensive insulin therapy and weight gain in IDDM. Diabetes 42:1700-1707, 1993
93. Woods SC, Figlewicz Lattemann DP, Schwanz MW, Porte D: A re-assessment of the regulation of adiposity and appetite by the brain insulin system. Int J Obes 14 (Suppl. 3):69-76, 1990
94. Schwartz MW, Seeley RJ: Neuroendocrine responses to starvation and weight loss. N Engl J Med 336:1802-1811, 1997
95. Lasker RD: The Diabetes Control and Complications Trial: implications for policy and practice. N Engl J Med 329:1035-1056, 1993